IN8bio Past Earnings Performance
Past criteria checks 0/6
IN8bio's earnings have been declining at an average annual rate of -47%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-47.0%
Earnings growth rate
25.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -89.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How IN8bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -27 | 14 | 13 |
| 30 Jun 22 | 0 | -21 | 13 | 10 |
| 31 Mar 22 | 0 | -18 | 10 | 8 |
| 31 Dec 21 | 0 | -15 | 7 | 7 |
| 30 Sep 21 | 0 | -12 | 5 | 6 |
| 30 Jun 21 | 0 | -11 | 4 | 6 |
| 31 Mar 21 | 0 | -11 | 4 | 6 |
| 31 Dec 20 | 0 | -10 | 3 | 5 |
| 30 Sep 20 | 0 | -9 | 3 | 5 |
| 30 Jun 20 | 0 | -8 | 3 | 4 |
| 31 Mar 20 | 0 | -6 | 3 | 3 |
| 31 Dec 19 | 0 | -6 | 3 | 2 |
Quality Earnings: 6JH is currently unprofitable.
Growing Profit Margin: 6JH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6JH is unprofitable, and losses have increased over the past 5 years at a rate of 47% per year.
Accelerating Growth: Unable to compare 6JH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6JH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 6JH has a negative Return on Equity (-89.88%), as it is currently unprofitable.